Global Brain Delivery of Neprilysin Gene by Intravascular Administration of AAV Vector in Mice
Authors
Affiliations
Accumulation of amyloid-β peptide (Aβ) in the brain is closely associated with cognitive decline in Alzheimer's disease (AD). Stereotaxic infusion of neprilysin-encoding viral vectors into the hippocampus has been shown to decrease Aβ in AD-model mice, but more efficient and global delivery is necessary to treat the broadly distributed burden in AD. Here we developed an adeno-associated virus (AAV) vector capable of providing neuronal gene expression throughout the brains after peripheral administration. A single intracardiac administration of the vector carrying neprilysin gene in AD-model mice elevated neprilysin activity broadly in the brain, and reduced Aβ oligomers, with concurrent alleviation of abnormal learning and memory function and improvement of amyloid burden. The exogenous neprilysin was localized mainly in endosomes, thereby effectively excluding Aβ oligomers from the brain. AAV vector-mediated gene transfer may provide a therapeutic strategy for neurodegenerative diseases, where global transduction of a therapeutic gene into the brain is necessary.
Saxena S, Ansari S, Maurya V, Kumar S, Sharma D, Malhotra H ACS Pharmacol Transl Sci. 2024; 7(12):3645-3657.
PMID: 39698259 PMC: 11651204. DOI: 10.1021/acsptsci.4c00400.
Iwata N, Tsubuki S, Sekiguchi M, Watanabe-Iwata K, Matsuba Y, Kamano N Life Sci Alliance. 2024; 7(12).
PMID: 39348937 PMC: 11443169. DOI: 10.26508/lsa.202402650.
Ye D, Chukwu C, Yang Y, Hu Z, Chen H Adv Drug Deliv Rev. 2024; 211:115363.
PMID: 38906479 PMC: 11892011. DOI: 10.1016/j.addr.2024.115363.
A Metalloproteinase Cocktail from the Venom of Cleaves Amyloid Beta Peptides at the α-Cleavage Site.
Futai E, Kawasaki H, Sato S, Daoudi K, Hidaka M, Tomita T Toxins (Basel). 2023; 15(8).
PMID: 37624257 PMC: 10467146. DOI: 10.3390/toxins15080500.
Nucleic acid drug vectors for diagnosis and treatment of brain diseases.
Lu Z, Shen J, Yang J, Wang J, Zhao R, Zhang T Signal Transduct Target Ther. 2023; 8(1):39.
PMID: 36650130 PMC: 9844208. DOI: 10.1038/s41392-022-01298-z.